
Impax agrees to $35 million settlement over anticompetitive practices with Valeant generic
pharmafile | March 12, 2018 | News story | Sales and Marketing | Impax, Medicis, Solodyn, Valeant, generic, pharma
Impax Pharmaceuticals has acquiesced to paying a $35 million settlement in order to resolve part of an antitrust lawsuit it is facing related to allegations that it entered into an agreement to delay its own generic version of Valeant’s acne medication Solodyn from hitting the market.
According to the allegations, Impax accepted $40 million and $23 million in milestone payments from Valeant-owned Medicis back in 2008 after it agreed not to pursue an appeal to a court ruling on a lawsuit to invalidate a Solodyn patent. The company did not begin to market its generic version of the drug until 2011, despite securing FDA approval in 2009.
While it agreed to the payment, Impax did not admit liability. Consumers and insurers have reportedly been overcharged to the tune of $790.3 million as a result of the deal.
Valeant itself agreed to pay $58 million in February to resolve a class action lawsuit concerning Solodyn, a drug it acquired when it bought out Medicis Pharmaceutical in 2012.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …






